Myriad Genetics grants retention stock options to three executives, including CFO
On November 6, 2026, the Compensation and Human Capital Committee approved one-time retention stock option awards for certain executive officers, including three named executive officers: CFO Benjamin R. Wheeler, COO Mark S. Verratti, and CSO Dale Muzzey. The awards are intended to promote retention and continuity as the company executes initiatives to improve operational efficiencies and financial performance, and the options vest on the third anniversary of the grant date.
Key points
- Awards approved November 6, 2026, under the 2026 Employee, Director and Consultant Equity Incentive Plan.
- Shares subject to awards: Verratti (COO) 146,933; Wheeler (CFO) 121,379; Muzzey (CSO) 92,632.
- Exercise price equals the closing price of common stock on the grant date; options vest and become exercisable on the third anniversary, subject to continued service, and have a ten-year term.
- Form of stock option agreement filed as Exhibit 10.1.
The filing
Written by AI on Nov 9, 2026, 5:16 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.